Grace Therapeutics
GRCE
12 hedge funds and large institutions have $6.36M invested in Grace Therapeutics in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.
1% more capital invested
Capital invested by funds: $6.3M → $6.36M (+$62.6K)
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
1.99% less ownership
Funds ownership: 22.9% → 20.9% (-2%)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$43.2K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.3K |
| 3 |
JP Morgan Chase
New York
|
+$40 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$113K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$20.6K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$16.1K |
| 4 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$487 |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
-$18 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
1
ADAR1 Capital Management
Austin,
Texas
| $2.88M | – | – | – |
|
|
ACM
2
AIGH Capital Management
Baltimore,
Maryland
| $1.93M | – | – | – |
|
3
Bank of America
Charlotte,
North Carolina
| $1.48M | – | – | – |
|
|
4
Renaissance Technologies
New York
| $48.4K | +$43.2K | +16,147 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $8.2K | +$7.3K | +2,732 | New |
|
|
6
National Bank of Canada
Montreal,
Quebec, Canada
| $8.12K | -$487 | -182 | -6% |
|
7
Morgan Stanley
New York
| $5.65K | – | – | – |
|
|
8
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | -$16.1K | -6,041 | -92% |
|
|
AWM
9
Activest Wealth Management
Aventure,
Florida
| $312 | – | – | – |
|
|
10
UBS Group
Zurich,
Switzerland
| $84 | -$20.6K | -7,707 | -100% |
|
|
FDCDDQ
11
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $84 | – | – | – |
|
|
12
JP Morgan Chase
New York
| $51 | +$40 | +15 | +750% |
|
|
13
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$113K | -37,793 | Closed |
|
|
IA
14
IFP Advisors
Tampa,
Florida
| – | -$18 | -6 | Closed |
|
GRCE Hedge Fund Activity: Q3 2024 in Review
12 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q3 2024, worth a combined $6.36M — up 0.99% from $6.3M a quarter earlier.
Fund positioning in GRCE was balanced in Q3 2024: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $43.2K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $113K sold.
- 12 institutional investors held Grace Therapeutics (GRCE) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $6.36M of Grace Therapeutics stock for Q3 2024, up 0.99% quarter-over-quarter.
- 2 funds opened new Grace Therapeutics positions in Q3 2024 and 2 closed out, a net change of 0 holders.
- The largest Grace Therapeutics buyer in Q3 2024 was Renaissance Technologies, an estimated $43.2K added.
- The largest Grace Therapeutics seller in Q3 2024 was Susquehanna International Group, an estimated $113K sold.
Based on aggregated 13F filings for Q3 2024.